NCT02124668已完成2 期
A Phase 2, Multicenter, Single-arm, Open Label Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 4
- 主要终点
- Safety profile of enzalutamide assessed by adverse events (AEs), serious AEs (SAEs), vital signs, electrocardiograms (ECGs) and laboratory measurements
研究概览
简要总结
The purpose of this study is to monitor the safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subject has histologically or cytologically confirmed adenocarcinoma of the prostate
- •Subject has ongoing androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) analogue (agonist or antagonist) and plans to maintain throughout the study period or has had a prior orchiectomy (i.e., surgical or medical castration)
- •Subject has had at least one prior chemotherapy regimen for metastatic castration-resistant prostate cancer with at least one regimen containing docetaxel
- •Subject has progressive disease and indication for change of antineoplastic regimen
- •Subject has no known or suspected brain metastasis
- •Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- •Subject is able to swallow the study drug and comply with study requirements
- •There is no comparable or satisfactory alternative therapy to treat the subject's disease
- •Subject agrees not to participate in another interventional study while on treatment
排除标准
- •Subject has severe concurrent disease, infection, or co-morbidity that would make the subject inappropriate for enrollment
- •Subject's absolute neutrophil count is < 1000/μL, or platelet count < 100,000/μL, or hemoglobin < 6.2 mmol/L (or < 10 g/dL)
- •Subject's total bilirubin is ≥ 1.5 x upper limit of normal (ULN) (except for subjects with documented Gilbert's disease) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is ≥ 2.5x ULN
- •Subject's estimated creatinine clearance is less than 30 mL/min by the Cockcroft and Gault formula
- •Subject has albumin ≤ 30 g/L (or ≤ 3.0 g/dL)
- •Subject has received anti-androgen therapy (e.g. bicalutamide), chemotherapy, or biologic therapy for prostate cancer (other than bone targeted agents such as bisphosphonates or denosumab, gonadotropin-releasing hormone (GnRH) analogue therapy, or glucocorticoids which are allowed) within 4 weeks of Day 1
- •Subject has had prior use of abiraterone
- •Subject has prior use, or participation in a clinical trial, of an investigational agent that blocks androgen synthesis (e.g. TAK-700) or targets the androgen receptor (e.g. ARN-509, ODM-201)
- •Subject has:
- •A history of seizure, including any febrile seizure or any condition that may predispose to seizure including, but not limited to underlying brain injury, stroke, primary brain tumors, brain metastases,
- •A history of loss of consciousness or transient ischemic attack within 12 months of Screening
- •Subject has clinical signs suggestive of high or imminent risks for pathological fracture, spinal cord compression and/or cauda equina syndrome
- •Subject has a significant cardiovascular disease
- •Subject has received investigational therapy within 28 days or 5 half lives, whichever is longer, prior to Screening
- •Subject has undergone major surgery within 4 weeks prior to Screening
- •Subject has shown a hypersensitivity reaction to the active pharmaceutical ingredient or any of the capsule components, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene
- •Subject has used or plans to use, from 30 days prior to enrollment through the end of the study, medications known to lower the seizure threshold or prolong the QT interval
研究组 & 干预措施
Enzalutamide
Experimental
Enzalutamide
干预措施: Enzalutamide (Drug)
结局指标
主要结局
Safety profile of enzalutamide assessed by adverse events (AEs), serious AEs (SAEs), vital signs, electrocardiograms (ECGs) and laboratory measurements
时间窗: Up to 30 days after the last dose of enzalutamide or prior to the initiation of another anticancer therapy, whichever comes first (up to 18 months)
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT02528643Astellas Pharma Global Development, Inc.165
已完成
2 期
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast CancerAdvanced, Androgen Receptor Positive Triple Negative Breast CancerNCT01889238Pfizer118
已完成
2 期
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast CancerHER2 AmplifiedHuman Epidermal Growth Factor Receptor 2 (HER2)Advanced Breast CancerNCT02091960Astellas Pharma Global Development, Inc.103
已完成
4 期
Safety Study of Continued Enzalutamide Treatment In Prostate Cancer PatientsProstate CancerNCT01995513Pfizer509
已完成
不适用
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)Metastatic Castration Resistant Prostate CancerNCT02495974Astellas Pharma Europe Ltd.1,763